Is there a link between non-HDL cholesterol and blood pressure? An age and gender directed analysis of 7500 hypertensive outpatients

Journal fur Kardiologie

Volumn 19, Issue 1-2, 2012, Pages 11-16

  Lautsch, D ^a,b   Saely, C H ^a,c,d   Traindl, O ^e   Eber, B ^f   Pfeiffer, K P ^a,g   Drexel, Heinz ^a,c,d  

^a PRIVATE UNIVERSITY OF THE PRINCIPALITY OF LIECHTENSTEIN   (Liechtenstein)

^b MSD Austria   (Austria)

^c Department of Medicine and Cardiology   (France)

^d Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^e Landesklinikum Weinviertel ^*  (Austria)

^f Klinikum Kreuzschwestern Wels   (Austria)

^g University of Applied Sciences   (Austria)

Author keywords

Atherothrombotic disease; Blood pressure; Gender; Non HDL cholesterol

Indexed keywords

CHOLESTEROL;

ADULT; AGED; ARTICLE; AUSTRIA; BLOOD PRESSURE; DIASTOLIC BLOOD PRESSURE; FEMALE; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

EID: 84856778872     PISSN: 10240098     EISSN: 1680936X     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-57.
2. Anand SS, Islam S, Rosengren A, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Europ Heart J 2008; 29: 932-40.
3. Kotseva K, Wood D, De Backer, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 929-40.
4. Saely CH, Eber B, Pfeiffer KP, Drexel H, Low serum cholesterol in patients with type 2 diabetes; an analysis on two different patient populations. Intern J Cardiol 2010; 144: 394-8.
5. Lavie CJ, Milani RV, O'Keefe JH. To B or not to B: Is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B? Mayo Clin Proc 2010; 85: 446-50.
6. Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol Mech Dis 2006; 1: 297-329.
7. Safar ME, Levy BI, Struijker-Boudier. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003; 107: 2864-9.
8. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
9. Castelli WP, Anderson K. A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham study. Am J Med 1986; 80(2A): 23-32.
10. Nasri H, Yazdani M. The relationship between serum LDL-cholesterol, HDL-cholesterol and systolic blood pressure in patients with type 2 diabetes. Kardiol Pol 2006; 64: 1364-8.
11. Hjermann I, Helgeland A, Holme I, Lund-Larsen PG, Leren P. The association between blood pressure and serum cholesterol in healthy men: the Oslo study. J Epidemiol Comm Health 1978; 32: 117-23.
12. Bonaa KH, Thelle DS. Association between blood pressure and serum lipids in a population. The Tromso Study. Circulation 1991; 83: 1305-14.
13. Tonolo G, Melis MG, Formato M, et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000; 30: 980-7.
14. Feldstein CA. Statins in Hypertension: Are they a new class of antihypertensive agents? Am J Ther 2010; 17: 255-62.
15. Strazzullo P, Kerry SM, Barbato A, et al. Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension 2007; 49: 792-8.
16. Paulsen L, Holm C, Berch JN, et al. Effects of statins on renal sodium and water handling. Nephrol Dial Transplant 2008; 23: 1556-61.
17. Chopra V, Cholski PU, Cavusoglu E. Beyond lipid lowering: the anti-hypertensive role of statins. Cardiovasc Drugs Ther 2007; 21: 161-9.
18. Faggiotto A, Paoletti R. Statins and blockers of the renin-angiotensin system. Vascular protection beyond their primary mode of action. Hypertension 1999; 34: 987-96.
19. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive Cholesterol Reduction lowers blood pressure and large artery stiffness in Isolated Systolic Hypertension. J Am Coll Cardiol 2002; 39: 1020-5.
20. Bays HE, Rader DJ. Does nicotinic acid lower blood pressure? Int J Clin Pract 2009; 63: 151-9.
21. Bays HE, Maccubin D, Meehan AG. Blood pressure-lowering effects of extanded-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. Clin Ther 2009; 31: 115-22.
22. Canner PL, Furberg CD, McGovern ME. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the coronary drug project). Am J Cardiol 2006; 97: 477-9.
23. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
24. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
25. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart Disease and Stroke Statistics - 2009 Update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119: e21-e181.
26. Halperin RO, Sesso HD, Ma J, et al. Dyslipidemia and the risk of incident hypertension in men. Hypertension 2006; 47: 45-50.
27. Conroy RM, Pyörälä K, Fitzgerald AP. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Europ Heart J 2003; 24: 987-1003.
28. Knopp RH. Risk factors for coronary artery disease in women. Am J Cardiol 2002; 89: 28E-35E.
29. Davidson MH, Maki KC, Katz Karp S, Ingram KA. Management of hypercholesterolaemia in postmenopausal women. Drugs Aging 2002; 19: 169-78.
30. Paulsen L, Matthesen SK, Bech JN, Starklint J, Pedersen EB. Acute effects of atorvastatin on glomerular filtration rate, tubular function, blood pressure, and vasoactive hormones in patients with type 2 diabetes. J Clin Pharmacol 2010; 50: 816-22.
31. Nickenig G, Sachinidis A, Michaelsen F, et al. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95: 473-8.
32. Nickenig G, Bäumer AT, Temur Y, et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-4.
33. Vuagnat A, Giacché M, Hopkins PN, et al. Blood pressure response to angiotensin II, low density lipoprotein cholesterol and polymorphisms of the angiotensin II type 1 receptor gene in hypertensive sibling pairs. J Mol Med 2001; 79: 175-83.
34. Van der Linde N, Sijbrands E, Boomsma F, Van den Meiracker A. Effect of low-density lipoprotein cholesterol on angiotensin II sensitivity. A randomized trial with simvastatin. Hypertension 2006; 47: 1125-30.
35. Oren I, Brook JG, Gershoni-Baruch R. The D-Allele of the angiotensin-converting enzyme gene contributes towards blood LDL-cholesterol levels and the presence of hypertension. Atherosclerosis 1999; 145: 267-71.
36. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-72.
37. Messerli FH, Bangalore S, Egan BM, Julius S. Does life-long reduction in low-density lipoprotein cholesterol reduce the risk of new-onset hypertension? Am J Cardiol 2006; 98: 1122.